GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (STU:QIA) » Definitions » Cyclically Adjusted Price-to-FCF

Qiagen NV (STU:QIA) Cyclically Adjusted Price-to-FCF : 30.34 (As of Oct. 31, 2024)


View and export this data going back to . Start your Free Trial

What is Qiagen NV Cyclically Adjusted Price-to-FCF?

As of today (2024-10-31), Qiagen NV's current share price is €38.835. Qiagen NV's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was €1.28. Qiagen NV's Cyclically Adjusted Price-to-FCF for today is 30.34.

The historical rank and industry rank for Qiagen NV's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:QIA' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 29.55   Med: 44.97   Max: 80.62
Current: 30.89

During the past years, Qiagen NV's highest Cyclically Adjusted Price-to-FCF was 80.62. The lowest was 29.55. And the median was 44.97.

STU:QIA's Cyclically Adjusted Price-to-FCF is ranked better than
52.38% of 63 companies
in the Medical Diagnostics & Research industry
Industry Median: 30.67 vs STU:QIA: 30.89

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Qiagen NV's adjusted free cash flow per share data for the three months ended in Jun. 2024 was €0.534. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €1.28 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Qiagen NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Qiagen NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Cyclically Adjusted Price-to-FCF Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.67 72.19 61.76 42.56 35.13

Qiagen NV Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.42 33.13 35.13 32.50 30.05

Competitive Comparison of Qiagen NV's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Qiagen NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Cyclically Adjusted Price-to-FCF falls into.



Qiagen NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Qiagen NV's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=38.835/1.28
=30.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Qiagen NV's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.534/129.9100*129.9100
=0.534

Current CPI (Jun. 2024) = 129.9100.

Qiagen NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 0.241 99.960 0.313
201412 0.174 99.050 0.228
201503 0.158 99.750 0.206
201506 0.161 100.230 0.209
201509 0.285 100.500 0.368
201512 0.181 99.730 0.236
201603 0.107 100.310 0.139
201606 0.281 100.260 0.364
201609 0.281 100.570 0.363
201612 0.300 100.710 0.387
201703 0.147 101.440 0.188
201706 0.149 101.370 0.191
201709 0.170 102.030 0.216
201712 0.162 101.970 0.206
201803 0.051 102.470 0.065
201806 0.324 103.100 0.408
201809 0.173 103.950 0.216
201812 0.245 103.970 0.306
201903 -0.422 105.370 -0.520
201906 0.182 105.840 0.223
201909 0.241 106.700 0.293
201912 0.241 106.800 0.293
202003 -0.048 106.850 -0.058
202006 0.050 107.510 0.060
202009 -0.186 107.880 -0.224
202012 0.733 107.850 0.883
202103 0.275 108.870 0.328
202106 0.406 109.670 0.481
202109 0.394 110.790 0.462
202112 0.569 114.010 0.648
202203 0.687 119.460 0.747
202206 0.570 119.050 0.622
202209 0.837 126.890 0.857
202212 0.328 124.940 0.341
202303 0.136 124.720 0.142
202306 0.322 125.830 0.332
202309 0.350 127.160 0.358
202312 0.406 126.450 0.417
202403 0.385 128.580 0.389
202406 0.534 129.910 0.534

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Qiagen NV  (STU:QIA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Qiagen NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV Headlines

No Headlines